UBS Group Lowers CureVac (NASDAQ:CVAC) Price Target to $12.00

CureVac (NASDAQ:CVAC) had its price objective cut by equities research analysts at UBS Group from $13.00 to $12.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target would indicate a potential upside of 252.94% from the stock’s previous close.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Performance

CVAC opened at $3.40 on Wednesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.20 and a quick ratio of 6.19. The business has a fifty day simple moving average of $3.05 and a 200 day simple moving average of $3.19. CureVac has a 1 year low of $2.37 and a 1 year high of $5.28. The company has a market capitalization of $762.75 million, a PE ratio of 6.18 and a beta of 2.48.

CureVac (NASDAQ:CVAC) last announced its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). CureVac had a net margin of 20.72% and a return on equity of 21.98%. The business had revenue of $15.44 million during the quarter, compared to the consensus estimate of $6.40 million. Research analysts expect that CureVac will post 0.72 EPS for the current year.

Institutional Investors Weigh In On CureVac

Institutional investors and hedge funds have recently bought and sold shares of the company. Ballentine Partners LLC lifted its holdings in shares of CureVac by 81.8% during the 1st quarter. Ballentine Partners LLC now owns 31,573 shares of the company’s stock worth $88,000 after acquiring an additional 14,210 shares during the period. Greenleaf Trust bought a new stake in CureVac during the first quarter worth $31,000. Two Sigma Advisers LP acquired a new stake in shares of CureVac in the 4th quarter valued at $48,000. Two Sigma Investments LP bought a new position in shares of CureVac in the 4th quarter valued at $391,000. Finally, D. E. Shaw & Co. Inc. acquired a new position in shares of CureVac during the 4th quarter worth $66,000. Institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.